The relationship between serum leptin, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 levels and clinical parameters in primary fibromyalgia patients

Basit Öğe Kaydı
dc.contributor.authorAtamer, Yildiz
dc.contributor.authorSahbaz, Tugba
dc.contributor.authorAsik, Hatice Kubra
dc.contributor.authorSarac, Serdar
dc.contributor.authorAtamer, Aytac
dc.date.accessioned2024-03-13T10:33:06Z
dc.date.available2024-03-13T10:33:06Z
dc.date.issued2023
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractOBJECTIVE: The aim of this study was to investigate the levels of leptin, growth hormone, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 and their relations with clinical parameters in patients with primary fibromyalgia and healthy controls.METHODS: Our study was performed on 30 female patients with primary fibromyalgia and 30 healthy controls. The levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 were measured by a two-site immunoradiometric assay. The serum level of leptin was measured by the ELISA kit.RESULTS: The serum level of leptin was significantly higher, but the serum levels of insulin-like growth factor-1 were significantly lower in patients with fibromyalgia syndrome than healthy controls (p<0.001). The leptin level was positively correlated with the Visual Analog Scale, Fibromyalgia Impact Questionnaire score, Beck Depression Inventory score, tender point count, age, and duration of disease (p<0.001), but it was negatively correlated with insulin-like growth factor-1 (p<0.001). The insulin-like growth factor-1 level was negatively correlated with age, Visual Analog Scale, Fibromyalgia Impact Questionnaire and Beck Depression Inventory scores, duration of disease, and tender point count (p<0.001).CONCLUSION: Our results indicate that high levels of serum leptin and low levels of serum insulin-like growth factor-1 may play a role in the physiopathogenesis of fibromyalgia and may be related to some symptoms.en_US
dc.identifier.doi10.1590/1806-9282.20230240
dc.identifier.issn0104-4230
dc.identifier.issn1806-9282
dc.identifier.issue10en_US
dc.identifier.pmid37792867en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1590/1806-9282.20230240
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3767
dc.identifier.volume69en_US
dc.identifier.wosWOS:001083959300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Medica Brasileiraen_US
dc.relation.ispartofRevista Da Associacao Medica Brasileiraen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFibromyalgiaen_US
dc.subjectLeptinen_US
dc.subjectGrowth hormoneen_US
dc.subjectIGF-1en_US
dc.subjectIGFBP-3en_US
dc.titleThe relationship between serum leptin, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 levels and clinical parameters in primary fibromyalgia patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu